Piercarlo S. P.
- Country
- Italy
- Department
- U.O Reumatologia
Research Overview
- A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with Hyperuricemia
- Open-Label Extension Study Evaluating Long-Term Safety and Tolerability of Subcutaneous Secukinumab in Patients with Polymyalgia Rheumatica
- Evaluation of the Analgesic Efficacy and Safety of DFL24412 Versus Ketoprofen Lysine Salt in Patients with Chronic Low Back Pain
Data & Insights
Has run more than one trial at 69 of 172 partner sites.
Specializations
Rheumatic Conditions
The investigator specializes in the treatment of polymyalgia rheumatica (PMR), conducting research on innovative therapeutic approaches including biological treatments and glucocorticoid management strategies.
- PMR Treatment Optimization
- Glucocorticoid Tapering Protocols
- Long-term Disease Management
Clinical expertise extends to evaluating novel therapeutic agents for sustained disease remission.
Autoimmune Disorders
Focused on advancing treatment options for Sjögren's Syndrome, particularly investigating new therapeutic approaches for patients with moderate to severe systemic manifestations.
- Systemic Disease Activity
- Novel Therapeutic Agents
- Symptom Management
Expertise in evaluating treatments that address both systemic and localized manifestations of autoimmune conditions.
Metabolic Disorders
Active in researching treatments for gout with hyperuricemia, with particular attention to comparative therapeutic approaches and chronic pain management including chronic low back pain.
- Uric Acid Management
- Pain Control Strategies
- Therapeutic Comparisons
Specialized in evaluating novel therapeutic compounds for metabolic and pain conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.